NDAORALSYRUPPriority Review
Approved
Feb 1968
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
2/8 — Basic
Priority Review
SYMMETREL (amantadine hydrochloride) by Teva is clinical pharmacology pharmacodynamics mechanism of action antiviral the mechanism by which amantadine exerts its antiviral activity is not clearly understood. First approved in 1968.
Drug data last refreshed 3d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
SYMMETREL (amantadine hydrochloride) is an oral antiviral and neuroprotective small molecule approved in 1968 for schizophrenia and schizoaffective disorder. It works primarily as an M2 protein inhibitor in antiviral contexts and exhibits NMDA receptor antagonism with dopaminergic effects in neuropsychiatric applications. The drug is available as a syrup formulation and represents one of the oldest agents in the antipsychotic arsenal.
LOE Approaching
As an older generic approaching LOE, SYMMETREL likely has minimal dedicated brand team and declining portfolio prioritization, signaling limited career growth opportunities in traditional brand roles.
Mechanism of Action
CLINICAL PHARMACOLOGY Pharmacodynamics Mechanism of Action Antiviral The mechanism by which amantadine exerts its antiviral activity is not clearly understood. It appears to mainly prevent the release of infectious viral nucleic acid into the host cell by interfering with the function of the…
Worked on SYMMETREL at Teva? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.